Tuberosklerozda mTOR İnhibitörleri ve Diğer Tedaviler

Read full text Summarise with VIRAT
Authors: Sebahattin Vurucu
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder affecting multiple organ systems and is characterized by hamartomatous lesions in the central nervous system, skin, kidneys, heart, lungs, and eyes. Although its clinical course is variable, prognosis is largely determined by the extent of neurological and systemic involvement. Epilepsy, neuropsychiatric disorders, cutaneous and oral-dental lesions, ophthalmic involvement, renal and pulmonary disease, cardiac manifestations, and brain tumors are the main clinical conditions requiring treatment in TSC. Current therapeutic approaches aim to control symptoms and improve quality of life, and targeted treatment options have expanded considerably with the introduction of mTOR inhibitors. Conclusion: Treatment of TSC should be individualized and managed within a multidisciplinary framework due to its multisystem involvement. Vigabatrin is recommended as the first-line therapy for epilepsy, while alternative antiseizure medications, cannabidiol, and everolimus may be used in drug-resistant cases. When necessary, surgical interventions, laser ablation, ketogenic diet, and neurostimulation therapies can also be applied. Most organ manifestations are asymptomatic and require only regular follow-up; however, topical or systemic mTOR inhibitors as well as surgical and interventional treatments are indicated in clinically significant cases. Early diagnosis and personalized treatment strategies significantly improve long-term prognosis and quality of life in individuals with TSC. Keywords: Tuberous sclerosis complex, epilepsy, mTOR inhibitors, treatment approach

Fields of Study & Subjects

Tuberous Sclerosis Complex Research Epilepsy research and treatment PI3K/AKT/mTOR signaling in cancer

Publication details

Journal / source
Yüksek İhtisas Üniversitesi Sağlık Bilimleri Dergisi
Publication date
1 January 2026
Language
EN